Belimumab

BNF:
10.1.3
Status:
Do Not Prescribe (DNP), Red
Decision Date:
July 2016
 

Comments

RED: NICE TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus. This guidance updates and replaces NICE TA397.(Decision date - February 2022)

DNP: NICE TA806 - Belimumab for treating lupus nephritis (terminated appraisal) (Decision date - August 2022)

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app